An Open-Label, Phase II Study of Weekly ABI-007 as First Line Therapy for Patients With Metastatic Breast Cancer

Trial Profile

An Open-Label, Phase II Study of Weekly ABI-007 as First Line Therapy for Patients With Metastatic Breast Cancer

Discontinued
Phase of Trial: Phase II

Latest Information Update: 07 Jun 2016

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 19 Jun 2014 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 09 Sep 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Feb 2010 Planned end date changed from 1 Mar 2011 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top